Skip to main content
AmigoFish

EP 254: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent Richards of 5 Prime Sciences

From The Genetics Podcast · · 41 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

This week on The Genetics Podcast, Patrick is joined by Dr. Brent Richards, CEO and Founder of 5 Prime Sciences and Professor of Human Genetics, Epidemiology, and Medicine at McGill University. They discuss how to triangulate different types of genetic evidence to validate a drug target, why herd psychology often drives which targets get funded, why strong genetic support didn't save the Zeus IL-6 trial, and how collider bias can distort genetically stratified clinical trials.

Show Notes

0:00 Intro to The Genetics Podcast

00:59 Welcome to Brent

01:43 How company size shapes access to genetic drug discovery tools

04:10 Brent's framework for triangulating different types of genetic evidence

06:50 The herd psychology behind which drug targets get funded

10:01 Potential reasons the Zeus IL-6 trial failed despite strong genetic evidence

12:49 What a gold standard genetic evidence package actually looks like

17:13 Closing the data gap with diverse genomes and systematic pipelines

19:03 The diabetes patient story that drove Brent into drug development and balancing academia with industry

25:39 Why obesity went from a drug development graveyard to its biggest frontier

29:13 How collider bias can distort genetic risk trial results

38:20 Where to go deeper on advanced genetic drug discovery concepts

40:11 Closing remarks

Find out more:

- 5PrimeSciences’ symposium (https://5primesciences.com/symposium2026/) on human genetics at ASHG2026 in October

Back to The Genetics Podcast · Report a problem